Press Releases
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
EF launches search for strategic partner in bid to become world’s best cycling team
Additional investment builds on EF’s existing commitment and will go towards building Tour de France Femmes winning squad and long-term talent development on men’s and U23 squads CAMBRIDGE, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) — EF (Education First) is launching
EF launches search for strategic partner in bid to become world’s best cycling team
Additional investment builds on EF’s existing commitment and will go towards building Tour de France Femmes winning squad and long-term talent development on men’s and U23 squads CAMBRIDGE, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) — EF (Education First) is launching
EF launches search for strategic partner in bid to become world’s best cycling team
Additional investment builds on EF’s existing commitment and will go towards building Tour de France Femmes winning squad and long-term talent development on men’s and U23 squads CAMBRIDGE, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) — EF (Education First) is launching
EF launches search for strategic partner in bid to become world’s best cycling team
Additional investment builds on EF’s existing commitment and will go towards building Tour de France Femmes winning squad and long-term talent development on men’s and U23 squads CAMBRIDGE, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) — EF (Education First) is launching